Risankizumab for narrowed Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new medicine called risankizumab for people with Crohn's disease that has caused a narrowing (stricture) in the intestine. It compares risankizumab to another drug, ustekinumab, to see which works better for this type of Crohn's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have Crohn's disease with a narrowed (fibrostenotic) part of your intestine, confirmed by a scope or imaging.
- You have symptoms of a partial blockage, like belly cramps, vomiting after meals, or food restrictions.
- You have tried at least one other Crohn's medicine (like a TNF-inhibitor or azathioprine) and it didn't work or you can't take it.
- You have never taken risankizumab or ustekinumab before, and if you've been on other biologics, you stopped them at least 8 weeks ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
This trial tests ustekinumab, a medicine that calms immune inflammation, to see if it can improve symptoms in people with Crohn’s disease that causes bowel narrowing. It may help if your Crohn’s symptoms come from strictures (narrowed areas) seen on scans or endoscopy.
This study follows children with Crohn's disease who have already started taking risankizumab. It aims to see how well the treatment works in real-world use.
This study looks at treatments for a new (de novo) narrow area in the bowel from Crohn’s disease. It aims to see which treatment works better at relieving blockage-type symptoms for the safest, most effective option.
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.